Providing custom tailored, high quality preclinical services to prime your drugs for success.
We offer expert solutions for optimal preclinical testing
- standardized efficacy evaluation platforms
- long standing expertise in preclinical testing
- humanized precision models
- unique animal models mimicking the complexity of human disease
- over 100 therapeutics successfully tested
- scientific excellence
Our agent in Korea
LATEST NEWS & BLOG
Biomedcode has been selected to join the EUGATEWAY Healthcare and Medical Technologies Business Mission to Singapore on 8-11 December 2020.
Pro-Infliximab, which is only selectively active at the site of the disease, is shown to effectively treat arthritis while leaving unaffected the host immune responses to Listeria infection.
The sensitivity of the Tg197 arthritis preclinical evaluation platform allowed the translation of the superiority of anti-hTNF VNARs in an in vivo setting, demonstrating their potential as next generation anti-TNF therapies.
PRECLINICAL SERVICES DELIVERED
OUR CLIENTS SAY
"Our company had a pleasant experience of productive collaboration with Biomedcode s.a. in 2015. We would like to especially highlight the high quality of the study protocol preparation and report writing as well as efficient communication with Biomedcode’s CEO. We greatly appreciate your professionalism and looking forward to our future collaboration."
"We have several collaborations with Biomedcode, their scientific and efficient experiment schedules made each collaboration accomplished according to plan. From Biomedcode, we obtained convincing study reports and detailed records, which saved a lot of time for us in whole pre-clinical stage. We believe contracting professional works to such a professional and sophisticated group is a wise choice."
"It was a great pleasure working with Biomedcode that exhibited great expertise in preclinical testing and handled all the steps of the study with great professionalism always abiding by the terms of the agreement and always staying in close communication with us making this a very productive collaboration."
"The authors acknowledge the role of BioMedCode relating to studies involving the human Tg197 TNF transgenic mouse model of polyarthritis in identifying sensitive study designs to optimally address efficacy comparability in this well-establish and characterized disease model"
"…that was a pleasure to work with Biomedcode. Perfect in every aspect: study design, correspondence, preparation of the report, timing, additional discussions and etc. Biomedcode was recommended to us by the other company and after working with them we highly recommend Biomedcode to everyone."
Our new publication in Arthritis Research and Therapy presents a new mouse model recapitulating the specificity and complexity of human spondyloarthritis
Our PLOS Computational Biology paper presents a new analytical approach that can serve as powerful tool to evaluate and compare arthritis treatments
Biomedcode scientists coauthor a publication in Annals of Rheumatic diseases showing that Tg197 mice develop heart valve pathology sharing common...